BIOTECH ASSISTANT / FIELD NOTES

Review examines cocrystal performance and barriers to clinical translation

Academic source · Frontiers in Chemistry

Source published: 2026-11-03 · Event / reporting date: 2026-11-03

Site published: 2026-11-06 · Updated: 2026-11-06

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What the paper reports

A Frontiers in Chemistry review examines pharmaceutical cocrystals as a way to modify dissolution and related biopharmaceutical properties without changing an API's chemical identity. The abstract distinguishes solubility-limited BCS II drugs from permeability-limited BCS IV drugs. It highlights gastrointestinal instability, manufacturing reproducibility, coformer selection, and limited pharmacokinetic evidence. Much of the reported performance evidence remains preclinical.

Why this paper is included

Analysis: The review may help teams evaluate when solid-form engineering warrants further development and which stability, scale-up, and PK questions need testing.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Pharmaceutical solid state Formulation Development & Manufacturing

Related updates

2026-11-04Crystal Pharmatech / PR Newswire

Crystal Pharmatech updates ED-1 service information in November 4 English announcement

Crystal Pharmatech’s November 4 announcement confirms ED-1 service in Suzhou. Its service page describes integration with solid-form screening for small crystals and pharmaceutical solid forms.

MicroED structure determination Pharmaceutical solid state Ask AI ↗

2026-11-02AAPS Open

Compaction density reveals reversible urea polymorph changes under pressure

An AAPS Open study used a compaction simulator to track reversible density changes in urea between 600 and 900 MPa, consistent with its known form I-to-III transformation. The original abstract proposes in-die density monitoring as a material-sparing screen for pressure-induced phase changes. Applicability depends on a sufficiently large density difference; urea is the demonstrated model compound.

Pharmaceutical solid state Formulation Development & Manufacturing Ask AI ↗

2026-10-29Crystal Growth & Design (ACS)

Water-based spherical crystallization improves drug-particle flow

Researchers produced spherical cyclandelate and cyclandelate–tenoxicam particles in water using thermally induced liquid–liquid phase separation. Stirring controlled droplet and particle-size distributions. Under selected conditions, angles of repose fell by roughly 43%–46% versus raw materials. The study combines particle measurements with molecular simulations; it does not establish improved clinical performance or commercial-scale manufacturability.

Pharmaceutical solid state Ask AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗